Posted on 9/12/17
Johnson & Johnson: How To Decrease Your Investment Returns
Writing options for great companies such as Johnson & Johnson (JNJ) is a sure way to decrease your returns. Option writing seems to be a fashionable . . .
Posted on 9/12/17
Teva Is Worth Considering In This Buoyant Market
IntroductionWave upon wave of bad news has hits Teva (TEVA) of late. The company announced abysmal quarterly results which saw its lead product suffer from generic . . .
Posted on 9/12/17
Why Teva Pharmaceutical Industries Ltd. (ADR) Is Soaring
What happenedAfter announcing that it has officially filled its vacant CEO seat, Teva Pharmaceutical Industries (NYSE:TEVA), a pharma company primarily focused on generic drugs, jumped 18% . . .
Posted on 9/12/17
Insmed Announces Closing of Public Offering
BRIDGEWATER, N.J., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its common stock. Insmed . . .
Posted on 9/12/17
Johnson & Johnson Finally Getting A Little Help
Johnson & Johnson (NYSE:JNJ) is a stock I’ve recently come around to liking. In the past, I’ve thought the valuation to be a bit much and . . .
Posted on 9/11/17
MTBC Announces Full Repayment of Opus Bank Term Debt
MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP) a provider of proprietary, cloud-based healthcare IT solutions and services, today announced that it has fully repaid its $8 million term . . .
Posted on 9/11/17
Is Amicus Therapeutics Stock Still a Strong Buy?
What happenedAccording to data from S&P Global Market Intelligence, shares of rare-disease drugmaker Amicus Therapeutics (NASDAQ:FOLD) rose by 6.6% last month. Although the company did provide . . .
Posted on 9/11/17
Incyte Prices Public Offering of 4,945,000 Shares of Common Stock
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced the pricing of its underwritten public offering of 4,945,000 shares of its common stock. The Company has granted . . .
Posted on 9/10/17
Johnson & Johnson: (Some) More Room To Go
J&J has picked up 14% since we recommended it early this year, driven by strong execution and optimism regarding a recent acquisition that could buttress its . . .
Posted on 9/8/17
Johnson & Johnson's New Focus
IntroductionJohnson & Johnson (JNJ) has been one of the safest investments in the healthcare sector for many years. Its size, diversification, and dividend growth have long . . .
Posted on 9/8/17
Thoughts On Celgene Rising Despite Negative News Today
Introduction - Celgene not as strong as Hurricane Irma, but pretty strong nonethelessThe biotech I have championed most strongly for the past 11 months, Celgene (NASDAQ:CELG), . . .
Posted on 9/8/17
Buy Johnson & Johnson Before Q3 Earnings
Johnson & Johnson (JNJ) will beat on EPS and revenue when Q3 earnings are released on Oct. 17th fueled in part by the integration of Actelion . . .
Posted on 9/7/17
Celgene (CELG) Presents at Robert W Baird Global Healthcare Broker Conference (Transcript)
Celgene Corp (NASDAQ:CELG)Robert W Baird Global Healthcare Broker ConferenceSeptember 07, 2017, 15:45 ETExecutivesPeter Kellogg - CFO, CAO & Executive VPAnalystsBrian Skorney - Robert W. Baird & . . .
Posted on 9/7/17
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
What happenedShares of Spark Therapeutics Inc. (NASDAQ:ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The . . .
Posted on 9/7/17
Insmed Announces Pricing of Public Offering of Common Stock
BRIDGEWATER, N.J., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced an offering of 12,281,000 shares of its common stock in . . .
Posted on 9/7/17
Promius Pharma Named PM360 Trailblazer 2017 Company of the Year
PM360, a publication for marketing decision-makers in the pharmaceutical, biotech, and medical device industries, recently named Promius Pharma LLC as a finalist for the Trailblazer Company . . .
Posted on 9/6/17
Mid-Atlantic Dental Partners Raises $12.5 Million
Mid-Atlantic Dental Service Holdings LLC, operating as Mid-Atlantic Dental Partners, a dental support organization
Posted on 9/6/17
Johnson & Johnson's (JNJ) Management Presents at 2017 Barclays Global Consumer Staples Conference (Transcript)
Johnson & Johnson (NYSE:JNJ)2017 Barclays Global Consumer Staples Conference CallSeptember 05, 2017 12:45 PM ETExecutivesJorge Mesquita - EVP, Worldwide Chairman, ConsumerAnalystsLauren Lieberman - Barclays CapitalLauren LiebermanSo, . . .
Posted on 9/6/17
Teva Receives FDA Approval, But It Won't Be Enough
Recently, Teva (TEVA) received FDA approval for Austedo, which is a drug used to treat a movement disorder known as tardive dyskinesia. The problem is that . . .
Posted on 9/5/17
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Two of the biggest pharmaceutical companies in the world have been around since the 19th century. Eli Lilly and Company (NYSE:LLY) was founded in 1876, while . . .
Posted on 9/5/17
GlaxoSmithKline Is Wasting Money Paying a Dividend
As a general rule, I love companies that pay big dividends -- and British pharmaceutical giant GlaxoSmithKline (NYSE:GSK) pays some of the best dividends on the . . .
Posted on 9/4/17
AIO Announces Affiliation With Genovese Ophthalmic Associates
AIO (Associates in Ophthalmology), an eye care and surgery practice now with eight locations in the region, today announced a new partnership with Genovese Ophthalmic Associates . . .
Posted on 9/4/17
Tenet and Paladin Healthcare Reach Agreement to Transfer Ownership of Tenet’s Philadelphia Hospitals
PHILADELPHIA--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE:THC) and Paladin Healthcare today announced that they have entered into a definitive agreement for the sale of Tenet’s Hahnemann University Hospital, . . .
Posted on 9/4/17
Johnson & Johnson: How Does An $11 Special Dividend Sound To You?
The price Johnson & Johnson (JNJ) paid for acquiring Actelion has most likely been a bit too high and destroyed shareholder wealth.Even through the acquisition of . . .
Posted on 9/1/17
Pfizer's FCF And Dividend Implications
Photo creditPfizer (PFE) – like its mega-cap pharma brethren – has long been reliant upon capital returns to satisfy shareholders. The dividend is huge at nearly . . .

